Personal tools

DOID:8692

From FANTOM5_SSTAR

Revision as of 16:52, 12 September 2014 by Autoedit (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Name:myeloid leukemia
Namespace:FANTOM
Xrefs:
links:

ICD9CM:205
ICD9CM:205.9
MSH:D007951
MSH:D015473
NCI:C3172
SNOMEDCT_2010_1_31:128934006
SNOMEDCT_2010_1_31:154587007
SNOMEDCT_2010_1_31:188732008
SNOMEDCT_2010_1_31:188743000
SNOMEDCT_2010_1_31:190047005
SNOMEDCT_2010_1_31:269631008
SNOMEDCT_2010_1_31:324170002
SNOMEDCT_2010_1_31:37810007
SNOMEDCT_2010_1_31:94717009

UMLS_CUI:C0023470
Synonyms: "LEUKEMIA MYELOGENOUS" EXACT [MTH:NOCODE]
"Myelogenous Leukemia in Remission" EXACT [NCI2004_11_17:C4899]
"myeloid granulocytic leukemia" EXACT [CSP2005:2004-4431]
"Myeloid leukaemia" EXACT [SNOMEDCT_2005_07_31:154587007]
"Myeloid leukaemia" EXACT [SNOMEDCT_2005_07_31:269631008]
"Myeloid leukaemia (category)" EXACT [SNOMEDCT_2005_07_31:128934006]
"Myeloid leukemia" EXACT [ICD9CM_2006:205]
"Myeloid leukemia (disorder)" EXACT [SNOMEDCT_2005_07_31:188732008]
"Myeloid leukemia in remission (disorder)" EXACT [SNOMEDCT_2005_07_31:94716000]
"Myeloid leukemia NOS (disorder)" EXACT [SNOMEDCT_2005_07_31:188743000]
"Myeloid leukemia, disease (disorder)" EXACT [SNOMEDCT_2005_07_31:324170002]
"Myeloid leukemia, disease [Ambiguous]" EXACT [SNOMEDCT_2005_07_31:94717009]
"Myeloid leukemia, no ICD-O subtype (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:37810007]
"Myeloid leukemia, NOS, without mention of remission" EXACT [SNOMEDCT_2005_07_31:94717009]
"Myeloid leukemias (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:190047005]
"Non-Lymphocytic Leukemia" EXACT [NCI2004_11_17:C3172]
"Other myeloid leukemia" EXACT []
"Other myeloid leukemia (disorder)" EXACT [SNOMEDCT_2005_07_31:188740002]
"Other myeloid leukemia (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:190159007]
"Other myeloid leukemia in remission" EXACT []
"Other myeloid leukemia NOS (disorder)" EXACT [SNOMEDCT_2005_07_31:188742005]
"Other myeloid leukemia NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:190051007]
"Other myeloid leukemia without mention of remission" EXACT []
"Unspecified myeloid leukemia in remission" EXACT []
"Unspecified myeloid leukemia without mention of remission" EXACT []
Alt_id: DOID:8878
DOID:8879
DOID:8910
DOID:9066
DOID:9126

Ontology association<br>Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies.<br><br>link to ontology dataset<br>data

Parents

is_a:DOID:1240(leukemia)



Children


is a:DOID:8552 (chronic myeloid leukemia),DOID:9119 (acute myeloid leukemia)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10454-106G4 (chronic myelogenous leukemia cell line:K562)
  • 10699-109G6 (acute myeloid leukemia (FAB M7) cell line:M-MOK)
  • 10718-109I7 (biphenotypic B myelomonocytic leukemia cell line:MV-4-11)
  • 10752-110D5 (leukemia, chronic megakaryoblastic cell line:MEG-01)
  • 10761-110E5
  • 10764-110E8 (acute myeloid leukemia (FAB M5) cell line:NOMO-1)

... further results Mouse (Mus musculus)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10454-106G4 (chronic myelogenous leukemia cell line:K562)
  • 10699-109G6 (acute myeloid leukemia (FAB M7) cell line:M-MOK)
  • 10718-109I7 (biphenotypic B myelomonocytic leukemia cell line:MV-4-11)
  • 10752-110D5 (leukemia, chronic megakaryoblastic cell line:MEG-01)
  • 10761-110E5
  • 10764-110E8 (acute myeloid leukemia (FAB M5) cell line:NOMO-1)

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:8692 (myeloid leukemia), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

P-valueFFCPShort description
5.17e-119FFCP PHASE2:Hg19::chr6:68598314..68598325,-#_592044a2434645483cf925012b6bba26p@chr6:68598314..68598325, -
5.17e-119FFCP PHASE1:Hg19::chr6:68598314..68598325,-#_592044a2434645483cf925012b6bba26p@chr6:68598314..68598325, -
2.45e-115FFCP PHASE2:Hg19::chr6:68598272..68598298,-#_00bce4cf8a8176fc22d257f3cfbb32e9p@chr6:68598272..68598298, -
2.45e-115FFCP PHASE1:Hg19::chr6:68598272..68598298,-#_00bce4cf8a8176fc22d257f3cfbb32e9p@chr6:68598272..68598298, -
9.64e-113FFCP PHASE2:Hg19::chr6:68596384..68596400,-#_ef875d98e5095f9245d965f5a26ea836p@chr6:68596384..68596400, -
9.64e-113FFCP PHASE1:Hg19::chr6:68596384..68596400,-#_ef875d98e5095f9245d965f5a26ea836p@chr6:68596384..68596400, -
9.04e-108FFCP PHASE2:Hg19::chr6:68592986..68593000,-#_e18dc17ce3c6bc45614762d5e51f4b3ep@chr6:68592986..68593000, -
9.04e-108FFCP PHASE1:Hg19::chr6:68592986..68593000,-#_e18dc17ce3c6bc45614762d5e51f4b3ep@chr6:68592986..68593000, -
9.6e-108FFCP PHASE2:Hg19::chr6:68598245..68598268,-#_53cf22b6eddc1884d054b7916c8e5561p@chr6:68598245..68598268, -
9.6e-108FFCP PHASE1:Hg19::chr6:68598245..68598268,-#_53cf22b6eddc1884d054b7916c8e5561p@chr6:68598245..68598268, -
4.74e-107FFCP PHASE1:Hg19::chr16:29674970..29675007,+#_e46193636e435b50c39d1d6870aa5546p4@SPN
4.74e-107FFCP PHASE2:Hg19::chr16:29674970..29675007,+#_e46193636e435b50c39d1d6870aa5546p4@SPN
7.65e-107FFCP PHASE1:Hg19::chr6:68598507..68598519,-#_e8598a4afd686b713a53aef6252fb888p@chr6:68598507..68598519, -
7.65e-107FFCP PHASE2:Hg19::chr6:68598507..68598519,-#_e8598a4afd686b713a53aef6252fb888p@chr6:68598507..68598519, -
1.74e-106FFCP PHASE2:Hg19::chr6:68598587..68598598,-#_26db9efbe7622e5b9ac5d2659ae8aa2ep@chr6:68598587..68598598, -
1.74e-106FFCP PHASE1:Hg19::chr6:68598587..68598598,-#_26db9efbe7622e5b9ac5d2659ae8aa2ep@chr6:68598587..68598598, -
3.12e-102FFCP PHASE2:Hg19::chr11:33913475..33913549,-#_439f1996fe65b219290de45bb6c7b3d4p5@LMO2
3.12e-102FFCP PHASE1:Hg19::chr11:33913475..33913549,-#_439f1996fe65b219290de45bb6c7b3d4p5@LMO2
1.29e-100FFCP PHASE1:Hg19::chr6:68593536..68593560,-#_3794a407a3f51d82607a73beddd2ca59p@chr6:68593536..68593560, -
1.29e-100FFCP PHASE2:Hg19::chr6:68593536..68593560,-#_3794a407a3f51d82607a73beddd2ca59p@chr6:68593536..68593560, -
1.29e-100FFCP PHASE1:Hg19::chr6:68591611..68591627,-#_3794a407a3f51d82607a73beddd2ca59p@chr6:68591611..68591627, -
1.29e-100FFCP PHASE2:Hg19::chr6:68591611..68591627,-#_3794a407a3f51d82607a73beddd2ca59p@chr6:68591611..68591627, -
3.05e-100FFCP PHASE2:Hg19::chr6:68597599..68597612,-#_c1dc5119f1f6c2562c6776633d1fd110p@chr6:68597599..68597612, -
3.05e-100FFCP PHASE2:Hg19::chr6:68596698..68596715,-#_c1dc5119f1f6c2562c6776633d1fd110p@chr6:68596698..68596715, -
3.05e-100FFCP PHASE1:Hg19::chr6:68597599..68597612,-#_c1dc5119f1f6c2562c6776633d1fd110p@chr6:68597599..68597612, -
3.05e-100FFCP PHASE1:Hg19::chr6:68596698..68596715,-#_c1dc5119f1f6c2562c6776633d1fd110p@chr6:68596698..68596715, -
3.05e-100FFCP PHASE2:Hg19::chr6:68596826..68596859,-#_c1dc5119f1f6c2562c6776633d1fd110p@chr6:68596826..68596859, -
3.05e-100FFCP PHASE1:Hg19::chr6:68596826..68596859,-#_c1dc5119f1f6c2562c6776633d1fd110p@chr6:68596826..68596859, -
2.22e-94FFCP PHASE1:Hg19::chr6:68593520..68593534,-#_f6a8e8f30050b6d5cf208ec6bfab83fbp@chr6:68593520..68593534, -
2.22e-94FFCP PHASE2:Hg19::chr6:68593520..68593534,-#_f6a8e8f30050b6d5cf208ec6bfab83fbp@chr6:68593520..68593534, -
2.22e-94FFCP PHASE2:Hg19::chr6:68595369..68595417,-#_f6a8e8f30050b6d5cf208ec6bfab83fbp@chr6:68595369..68595417, -
2.22e-94FFCP PHASE1:Hg19::chr6:68595369..68595417,-#_f6a8e8f30050b6d5cf208ec6bfab83fbp@chr6:68595369..68595417, -
5.19e-94FFCP PHASE2:Hg19::chr6:68596343..68596355,-#_1915ecbbc6c7a14ad999d4a1103fd535p@chr6:68596343..68596355, -
5.19e-94FFCP PHASE1:Hg19::chr6:68596343..68596355,-#_1915ecbbc6c7a14ad999d4a1103fd535p@chr6:68596343..68596355, -
5.19e-94FFCP PHASE2:Hg19::chr6:68596783..68596797,-#_1915ecbbc6c7a14ad999d4a1103fd535p@chr6:68596783..68596797, -
5.19e-94FFCP PHASE1:Hg19::chr6:68596783..68596797,-#_1915ecbbc6c7a14ad999d4a1103fd535p@chr6:68596783..68596797, -
2.16e-93FFCP PHASE1:Hg19::chr12:58329776..58329791,-#_28fd3ede83ad5ecca3e88d212b27915fp3@ENST00000547492
2.16e-93FFCP PHASE2:Hg19::chr12:58329776..58329791,-#_28fd3ede83ad5ecca3e88d212b27915fp3@ENST00000547492
2.3e-93FFCP PHASE1:Hg19::chr16:29675010..29675041,+#_bace72c1a831070a91aae056a6892b94p5@SPN
2.3e-93FFCP PHASE2:Hg19::chr16:29675010..29675041,+#_bace72c1a831070a91aae056a6892b94p5@SPN
1.84e-90FFCP PHASE1:Hg19::chr6:135513595..135513617,+#_7b16eca14af1691894c5386548426a08p4@MYB
1.84e-90FFCP PHASE2:Hg19::chr6:135513595..135513617,+#_7b16eca14af1691894c5386548426a08p4@MYB
7.75e-89FFCP PHASE2:Hg19::chr6:68596289..68596302,-#_0a250b49b6a1d989524042a0a816b735p@chr6:68596289..68596302, -
7.75e-89FFCP PHASE1:Hg19::chr6:68596289..68596302,-#_0a250b49b6a1d989524042a0a816b735p@chr6:68596289..68596302, -
3.71e-88FFCP PHASE1:Hg19::chr6:68592948..68592958,-#_1d931f894de404227ff5c8f77f6043fbp@chr6:68592948..68592958, -
3.71e-88FFCP PHASE2:Hg19::chr6:68592948..68592958,-#_1d931f894de404227ff5c8f77f6043fbp@chr6:68592948..68592958, -
3.94e-88FFCP PHASE2:Hg19::chr6:68598534..68598555,-#_4a60adce00ea2941868958cb6e3bd84bp@chr6:68598534..68598555, -
3.94e-88FFCP PHASE1:Hg19::chr6:68598534..68598555,-#_4a60adce00ea2941868958cb6e3bd84bp@chr6:68598534..68598555, -
4.46e-88FFCP PHASE2:Hg19::chr6:68593264..68593275,-#_28619220c6a520514e110ae8a731efa1p@chr6:68593264..68593275, -
4.46e-88FFCP PHASE1:Hg19::chr6:68593264..68593275,-#_28619220c6a520514e110ae8a731efa1p@chr6:68593264..68593275, -
8.57e-88FFCP PHASE2:Hg19::chr6:68596757..68596769,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68596757..68596769, -
8.57e-88FFCP PHASE1:Hg19::chr6:68596757..68596769,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68596757..68596769, -
8.57e-88FFCP PHASE2:Hg19::chr6:68597438..68597450,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68597438..68597450, -
8.57e-88FFCP PHASE1:Hg19::chr6:68597438..68597450,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68597438..68597450, -
8.57e-88FFCP PHASE1:Hg19::chr6:68593587..68593600,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68593587..68593600, -
8.57e-88FFCP PHASE1:Hg19::chr6:68593250..68593259,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68593250..68593259, -
8.57e-88FFCP PHASE2:Hg19::chr6:68593587..68593600,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68593587..68593600, -
8.57e-88FFCP PHASE2:Hg19::chr6:68593250..68593259,-#_0da74ce1b445a3abf766b57ce1959ee6p@chr6:68593250..68593259, -
5.52e-85FFCP PHASE2:Hg19::chr19:695494..695510,-#_5ee0be624e7ddb07321e6926ce14be31p3@PRSS57
5.52e-85FFCP PHASE1:Hg19::chr19:695494..695510,-#_5ee0be624e7ddb07321e6926ce14be31p3@PRSS57
2.57e-82FFCP PHASE1:Hg19::chr6:68593206..68593218,-#_def2b3423cf3b3fd2083dc6b36f3c1a6p@chr6:68593206..68593218, -
2.57e-82FFCP PHASE2:Hg19::chr6:68593206..68593218,-#_def2b3423cf3b3fd2083dc6b36f3c1a6p@chr6:68593206..68593218, -
5.22e-82FFCP PHASE2:Hg19::chr11:33913558..33913630,-#_256d933c99dd9022a255a445a0c6a940p4@LMO2
5.22e-82FFCP PHASE1:Hg19::chr11:33913558..33913630,-#_256d933c99dd9022a255a445a0c6a940p4@LMO2
1.37e-81FFCP PHASE1:Hg19::chr1:246350204..246350229,-#_8666f9191040fa9ef9129254f6e9633fp@chr1:246350204..246350229, -
1.37e-81FFCP PHASE2:Hg19::chr1:246350204..246350229,-#_8666f9191040fa9ef9129254f6e9633fp@chr1:246350204..246350229, -
1.37e-81FFCP PHASE2:Hg19::chr6:68598642..68598649,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68598642..68598649, -
1.37e-81FFCP PHASE2:Hg19::chr6:68598190..68598207,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68598190..68598207, -
1.37e-81FFCP PHASE1:Hg19::chr6:68598642..68598649,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68598642..68598649, -
1.37e-81FFCP PHASE1:Hg19::chr6:68598190..68598207,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68598190..68598207, -
1.37e-81FFCP PHASE2:Hg19::chr6:68595490..68595501,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68595490..68595501, -
1.37e-81FFCP PHASE1:Hg19::chr6:68595490..68595501,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68595490..68595501, -
1.37e-81FFCP PHASE2:Hg19::chr6:68594786..68594797,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68594786..68594797, -
1.37e-81FFCP PHASE1:Hg19::chr6:68594786..68594797,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68594786..68594797, -
1.37e-81FFCP PHASE2:Hg19::chr6:68595866..68595871,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68595866..68595871, -
1.37e-81FFCP PHASE1:Hg19::chr6:68595866..68595871,-#_8666f9191040fa9ef9129254f6e9633fp@chr6:68595866..68595871, -
5.76e-80FFCP PHASE1:Hg19::chr12:58329793..58329806,-#_3d87651c9a3554e2ad469f0659d84e0dp2@ENST00000547492
5.76e-80FFCP PHASE2:Hg19::chr12:58329793..58329806,-#_3d87651c9a3554e2ad469f0659d84e0dp2@ENST00000547492
7.15e-80FFCP PHASE2:Hg19::chr12:58329762..58329773,-#_4819ab8efe96b1eda738a6d484fab048p5@ENST00000547492
7.15e-80FFCP PHASE1:Hg19::chr12:58329762..58329773,-#_4819ab8efe96b1eda738a6d484fab048p5@ENST00000547492
2.02e-77FFCP PHASE2:Hg19::chr6:68599042..68599067,-#_13d7cb9d1e873e3f173c292716b6980dp1@uc003pes.1, p1@uc003pet.1
2.02e-77FFCP PHASE1:Hg19::chr6:68599042..68599067,-#_13d7cb9d1e873e3f173c292716b6980dp1@uc003pes.1, p1@uc003pet.1
9.17e-77FFCP PHASE1:Hg19::chr6:68593158..68593168,-#_c1b3ad390e8cec3feb187817bffde2b0p@chr6:68593158..68593168, -
9.17e-77FFCP PHASE2:Hg19::chr6:68593158..68593168,-#_c1b3ad390e8cec3feb187817bffde2b0p@chr6:68593158..68593168, -
1.66e-76FFCP PHASE2:Hg19::chr3:129297361..129297381,-#_54a8d98eb02c57a86adff03c403ae113p10@PLXND1
1.66e-76FFCP PHASE1:Hg19::chr3:129297361..129297381,-#_54a8d98eb02c57a86adff03c403ae113p10@PLXND1
9.78e-76FFCP PHASE1:Hg19::chr1:246269797..246269820,-#_23f6f34d9dc1cb87be3c91b40b84d91ap@chr1:246269797..246269820, -
9.78e-76FFCP PHASE2:Hg19::chr1:246269797..246269820,-#_23f6f34d9dc1cb87be3c91b40b84d91ap@chr1:246269797..246269820, -
1.3e-75FFCP PHASE2:Hg19::chr6:68598984..68598997,-#_5b44f6651ce7d6c22f47cceb067920c3p2@uc003pes.1, p2@uc003pet.1
1.3e-75FFCP PHASE1:Hg19::chr6:68598984..68598997,-#_5b44f6651ce7d6c22f47cceb067920c3p2@uc003pes.1, p2@uc003pet.1
1.92e-75FFCP PHASE1:Hg19::chr19:695576..695587,-#_eefb637c675628c8f907fef11a34a006p4@PRSS57
1.92e-75FFCP PHASE2:Hg19::chr19:695576..695587,-#_eefb637c675628c8f907fef11a34a006p4@PRSS57
2.14e-75FFCP PHASE2:Hg19::chr6:68598473..68598480,-#_f309833b2a1e99d92041cc58047650fep@chr6:68598473..68598480, -
2.14e-75FFCP PHASE1:Hg19::chr6:68598473..68598480,-#_f309833b2a1e99d92041cc58047650fep@chr6:68598473..68598480, -
2.14e-75FFCP PHASE2:Hg19::chr6:68598674..68598685,-#_f309833b2a1e99d92041cc58047650fep@chr6:68598674..68598685, -
2.14e-75FFCP PHASE1:Hg19::chr6:68598674..68598685,-#_f309833b2a1e99d92041cc58047650fep@chr6:68598674..68598685, -
2.95e-75FFCP PHASE1:Hg19::chr19:695467..695482,-#_2bc36cfe9ebe6843ab6425d5ff2b7d40p2@PRSS57
2.95e-75FFCP PHASE2:Hg19::chr19:695467..695482,-#_2bc36cfe9ebe6843ab6425d5ff2b7d40p2@PRSS57
7.95e-75FFCP PHASE2:Hg19::chr4:80132811..80132835,+#_4325d692b7fa7c3de87dc131e0098a6bp1@ENST00000437737
7.95e-75FFCP PHASE1:Hg19::chr4:80132811..80132835,+#_4325d692b7fa7c3de87dc131e0098a6bp1@ENST00000437737

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=DOID:8692&oldid=3275740"